You just read:

IBC Generium Selects Goodwin Biotechnology to Optimize the Process, Scale-Up, and Manufacture an IgG-based Bispecific Antibody for Phase I Clinical Trials

News provided by

Goodwin Biotechnology, Inc.

Apr 27, 2016, 11:59 ET